274 related articles for article (PubMed ID: 21817187)
21. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells.
Wies E; Mori Y; Hahn A; Kremmer E; Stürzl M; Fleckenstein B; Neipel F
Blood; 2008 Jan; 111(1):320-7. PubMed ID: 17890449
[TBL] [Abstract][Full Text] [Related]
22. Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival.
Wang C; Zhu C; Wei F; Zhang L; Mo X; Feng Y; Xu J; Yuan Z; Robertson E; Cai Q
J Virol; 2015 Oct; 89(20):10416-26. PubMed ID: 26246572
[TBL] [Abstract][Full Text] [Related]
23. Kaposi's sarcoma-associated herpesvirus vIRF2 protein utilizes an IFN-dependent pathway to regulate viral early gene expression.
Koch S; Damas M; Freise A; Hage E; Dhingra A; Rückert J; Gallo A; Kremmer E; Tegge W; Brönstrup M; Brune W; Schulz TF
PLoS Pathog; 2019 May; 15(5):e1007743. PubMed ID: 31059555
[TBL] [Abstract][Full Text] [Related]
24. Kaposi's sarcoma-associated herpesvirus K-bZIP protein is necessary for lytic viral gene expression, DNA replication, and virion production in primary effusion lymphoma cell lines.
Lefort S; Flamand L
J Virol; 2009 Jun; 83(11):5869-80. PubMed ID: 19321621
[TBL] [Abstract][Full Text] [Related]
25. Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.
Bottero V; Sadagopan S; Johnson KE; Dutta S; Veettil MV; Chandran B
J Virol; 2013 Nov; 87(21):11806-20. PubMed ID: 23986578
[TBL] [Abstract][Full Text] [Related]
26. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
Katano H
Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675
[TBL] [Abstract][Full Text] [Related]
27. Expression and Subcellular Localization of the Kaposi's Sarcoma-Associated Herpesvirus K15P Protein during Latency and Lytic Reactivation in Primary Effusion Lymphoma Cells.
Smith CG; Kharkwal H; Wilson DW
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835496
[TBL] [Abstract][Full Text] [Related]
28. Human herpesvirus 8 interleukin-6 contributes to primary effusion lymphoma cell viability via suppression of proapoptotic cathepsin D, a cointeraction partner of vitamin K epoxide reductase complex subunit 1 variant 2.
Chen D; Gao Y; Nicholas J
J Virol; 2014 Jan; 88(2):1025-38. PubMed ID: 24198402
[TBL] [Abstract][Full Text] [Related]
29. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7.
Kim YJ; Kim Y; Kumar A; Kim CW; Toth Z; Cho NH; Lee HR
PLoS Pathog; 2021 Jan; 17(1):e1009179. PubMed ID: 33471866
[TBL] [Abstract][Full Text] [Related]
30. Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.
Chandrasekharan JA; Huang XM; Hwang AC; Sharma-Walia N
J Virol; 2016 Dec; 90(24):11020-11031. PubMed ID: 27681120
[TBL] [Abstract][Full Text] [Related]
31. Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1.
Hu D; Wang V; Yang M; Abdullah S; Davis DA; Uldrick TS; Polizzotto MN; Veeranna RP; Pittaluga S; Tosato G; Yarchoan R
J Virol; 2016 Jan; 90(1):368-78. PubMed ID: 26491160
[TBL] [Abstract][Full Text] [Related]
32. Role of human herpesvirus 8 interleukin-6-activated gp130 signal transducer in primary effusion lymphoma cell growth and viability.
Cousins E; Nicholas J
J Virol; 2013 Oct; 87(19):10816-27. PubMed ID: 23903842
[TBL] [Abstract][Full Text] [Related]
33. Modulation of interferon regulatory factor 5 activities by the Kaposi sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3 contributes to immune evasion and lytic induction.
Bi X; Yang L; Mancl ME; Barnes BJ
J Interferon Cytokine Res; 2011 Apr; 31(4):373-82. PubMed ID: 21133648
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
Lan K; Murakami M; Bajaj B; Kaul R; He Z; Gan R; Feldman M; Robertson ES
Cancer Biol Ther; 2009 Nov; 8(22):2136-43. PubMed ID: 19783901
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
[TBL] [Abstract][Full Text] [Related]
36. Genetic Analyses of Contributions of Viral Interleukin-6 Interactions and Signaling to Human Herpesvirus 8 Productive Replication.
Li Q; Xiang Q; Chen D; Nicholas J
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669340
[TBL] [Abstract][Full Text] [Related]
37. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
Parravicini C; Chandran B; Corbellino M; Berti E; Paulli M; Moore PS; Chang Y
Am J Pathol; 2000 Mar; 156(3):743-9. PubMed ID: 10702388
[TBL] [Abstract][Full Text] [Related]
38. Modulation of Kaposi's sarcoma-associated herpesvirus interleukin-6 function by hypoxia-upregulated protein 1.
Giffin L; Yan F; Ben Major M; Damania B
J Virol; 2014 Aug; 88(16):9429-41. PubMed ID: 24920810
[TBL] [Abstract][Full Text] [Related]
39. Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections.
Sin SH; Eason AB; Bigi R; Kim Y; Kang S; Tan K; Seltzer TA; Venkataramanan R; An H; Dittmer DP
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021906
[TBL] [Abstract][Full Text] [Related]
40. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
